SG301

Phase 2Small molecule

HHangzhou Sumgen Biotech Co., Ltd.

SG301 is one of 96 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Nephrotic SyndromeActive, not recruiting

Multiple MyelomaActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Nephrotic SyndromePhase 2

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Adriamycin

GGynecologic Oncology Group

Preclinical

9 5

Nolvadex

AstraZeneca

Preclinical

1 6

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 7

SG301

HHangzhou Sumgen Biotech Co., Ltd.

Phase 2

1 8

Intron a

Systemic Therapy

1 10

Abecma

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Systemic Lupus Erythematosus

NCT06144710

Q4 2027

Phase 2Not yet recruiting

Systemic Lupus Erythematosus

NCT07447986

Q1 2028

Phase 3Recruiting

Relapsed/refractory Multiple Myeloma

NCT06508983

Q3 2029

Phase 2Recruiting

Nephrotic Syndrome

NCT07087314

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus2 trials

SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

Active, not recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Phase 1·NCT06144710·48 enrolled

To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus

Not yet recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Phase 2·NCT07447986·120 enrolled

Multiple Myeloma1 trial

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Active, not recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Phase 1·NCT04684108·61 enrolled

Nephrotic Syndrome1 trial

A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence

Recruiting·MMao Jianhua·Phase 2·NCT07087314·30 enrolled

Relapsed/Refractory Multiple Myeloma1 trial

A Phase 3 Randomized, Placebo-controlled, Double-blind, Multicenter Study Comparing SG301 in Combination With Pomalidomide and Dexamethasone Versus Placebo in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Phase 3·NCT06508983·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for SG301. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SG301 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SG301. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hangzhou Sumgen Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHangzhou Sumgen Biotech Co., Ltd.

SG301

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q1 2028

Q3 2029

Trials by Indication[1]

Systemic Lupus Erythematosus2 trials

Multiple Myeloma1 trial

Nephrotic Syndrome1 trial

Relapsed/Refractory Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News